GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $177M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 13.08.2021 | T1D Fund | t1dfund.or... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.08.2021 | Series A | $157M | - |
| 05.08.2020 | Seed | $20M | RA Capital... |
Mentions in press and media 11
| Date | Title | Description |
| 16.08.2021 | GentiBio Raises $157M in Series A Financing | GentiBio, Inc., a Boston, MA-based biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, closed a $157m Series A financing. The round was led by Matrix Capital Management with participation from ... |
| 11.08.2021 | The rise of startups…for startups | Good morning, Term Sheet readers. Finance reporter Anne Sraders here again, filling in for Lucinda while she’s on vacation. Paid Content What marketers need to know about trust From PwC If you’ve cracked a business newspaper or paid attenti... |
| 11.08.2021 | GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation | BOSTON, Aug. 11, 2021 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has closed on a Series A financing generating immediate proceeds o... |
| 11.08.2021 | The rise of startups…for startups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Winning the war for talent in the post-pandemic world From Future Forum by Slack Goo... |
| 11.08.2021 | GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation | - |
| 11.08.2021 | GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation | |
| 05.08.2020 | GentiBio Launches with $20M Seed Funding | BOSTON, MA, GentiBio has closed a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. >> Click here for more funding data on GentiBio >> To export GentiBio funding data to PDF and Excel,... |
| 05.08.2020 | Novartis-backed biotech startup GentiBio launches with $20M in seed funding to develop engineered regulatory T cells to deliver immune tolerizing therapies for autoimmune and inflammatory diseases | GentiBio, a Seattle-based biotherapeutics tech startup has closed a $20 million seed funding to develop engineered regulatory T cells to deliver immune tolerizing therapies for autoimmune and inflammatory diseases. The round was led by Orbi... |
| 05.08.2020 | GentiBio Raises $20M in Seed Funding | GentiBio, Inc., a Seattle, WA-based biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, closed a $20m seed funding. The round was l... |
| 05.08.2020 | GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimm... | - |
Show more